Active soluble post-translationally modified neuregulin isoforms

Active soluble post-translationally modified neuregulin isoforms

  • CN 105,561,299 A
  • Filed: 11/17/2008
  • Published: 05/11/2016
  • Est. Priority Date: 11/16/2007
  • Status: Active Application
First Claim
Patent Images

1. the solubility neuregulin-1 NRG-1 Neu Differentiation Factor NDF glial growth factors GGF isotype of restructuring is preparing the purposes in medicine, described medicine is used for the treatment of schizophrenia, particularly schizoid cognitive related fields, bipolar disorder and depression, Parkinson'"'"'s disease, Alzheimer'"'"'s disease, epilepsy, MS, ALS, apoplexy, traumatic brain injury and spinal cord injury, wherein said neuregulin-1 NRG-1 Neu Differentiation Factor NDF glial growth factors GGF isotype is the soluble human neuregulin-1 NRG-1 Neu Differentiation Factor NDF glial growth factors GGF isotype of restructuring, and wherein said neuregulin-1 NRG-1 Neu Differentiation Factor NDF glial growth factors GGF isotype have by SDS-PAGE measure about 15 to about 35KD molecular weight.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×